Countable Labs closed a $26 million financing round to scale commercial expansion of its single-molecule PCR technology. The company said it will also develop solutions for measurable residual disease (MRD) and applications in cell and gene therapy. The funding is positioned to accelerate productization and broader adoption of single-molecule PCR as a sensitive quantification tool, especially in oncology where MRD monitoring is increasingly used to guide treatment intensity. For biotech investors and tool developers, the round highlights continued capital flow into next-generation molecular diagnostics platforms that can shorten assay-to-decision timelines for clinical development and post-treatment monitoring.